AAB Member Resources
08/01/2014FDA Announces Intent to Publish Guidance Document for Oversight of LDTs
11/05/2013FDA Releases for Comment Draft Guidance for Industry Regarding Syphilis
05/30/2013FDA, ONC, FCC Seek Comments on a Risk-Based Regulatory Framework for Health IT - Comments Due 8/31/13
01/27/2012Bill Introduced by Congressman Burgess that would have CLIA Regulate Laboratory Developed Tests (LDTs)
01/06/2012FDA Issues Final Guidance for Industry: Current Good Tissue Practice and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products
08/11/2010AAB's Comments on FDA's "Oversight of Laboratory Developed Tests"
President Obama Nominates Margaret Hamburg as FDA Commissioner
FDA Adding 1,300 to Regulation Staff
Baxter Provides Update on Heparin Reactions
Draft Guidance for Industry, Clinical Laboratories, and FDA Staff
FDA CBER Regulation of HCT/Ps under 21 CFR Part 1271
The FDA Safety Information and Adverse Event Reporting Program
© The American Association of Bioanalysts. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
The American Association of Bioanalysts
906 Olive Street - Suite 1200, St. Louis, MO 63101-1448, 314-241-1445 - Fax 314-241-1449